Yeast Infection Treatment Market is Segmented By Pathogen Type(Candida Albicans, Candida Glabrata, Candida Rugosa, Others), By Infection Type(Vaginal Infection, Throat Infection, Skin Infection, Esophagus Infection, Others), By Drug Type(Polyene, Azole, Others), By Route of Administration(Oral, Intravenous, Others), By Distribution Channel(Retail Pharmacies, E-Commerce, Hospital), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Yeast infection treatment market size is growing at a high CAGR 5.2% during the forecast period (2023-2030).
Candidiasis, known as yeast infection, is a common type of fungal infection. Yeast infection can affect any human body region, including the skin, oral cavity, and intestines. Vaginal yeast infection, known as candidal vaginitis or candidal vulvovaginitis, is extremely common and widespread among women (CVV). Candida Albicans is the most usual fungus that causes vaginal yeast infection.
As per DataM Intelligence, Yeast Infection Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Yeast Infection Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Yeast Infection Treatment Market in the United States and Canada produces the utmost share. Whereas the European Yeast Infection Treatment Market is projected to continue its presence globally during the period of 2022- 2029.
Yeast Infection Treatment Market Dynamics
Itching, burning, swelling, rashes, and redness are some of the symptoms of a vaginal yeast infection, and the underlying causes are chronic antibiotic use, poor hygiene, lifestyle disease, and weakened immune. These reasons are expected to increase the demand for yeast infection treatment. The rising prevalence of cardiovascular, gastrointestinal, and other disorders is also expected to drive the yeast infection treatment market during the forecast period.
Rise in the prevalence of yeast infections will drive the market growth
The rise in the prevalence of yeast infections, the emergence of new fungal diseases, the increased use of antibiotics, which makes yeast infections resistant to them, and increased research and development on yeast infections are all expected to drive the market throughout the forecast period. According to several clinical research, 75 percent of women will get yeast infection once or twice. Furthermore, vaginal yeast infections are the second-most common cause of abnormal vaginal discharge in the United States.
According to National Center for Biotechnology Institute research, a yeast infection caused 1 billion individuals to suffer from skin, nail, and hair fungal infections in 2017, with 10 million suffering from mucosal candidiasis and 150 million suffering from serious fungal diseases. The rising prevalence of the HIV/AIDS pandemic, chronic obstructive pulmonary disease, asthma, and the rising incidence of malignancies are just a few factors expected to drive the yeast infection treatment market over the projected period.
According to National Center for Biotechnology Institute research, between 30 to 50 percent of women were impacted by vulvovaginal candidiasis at some point in their lives in 2018. In 2018, 40% of women in Germany reported incidences of vulvovaginal candidiasis. Candida species have been identified as the most frequent yeast infection in the Asia Pacific. Candidemia is the most frequent kind of invasive candidiasis in Australia, with an incidence rate of 0.05- 0.36 per 1000 people. All of these data are expected to increase the yeast infection treatment market during the projected period.
Side effects of medications is likely to hamper the market growth
However, side effects of medications, such as nausea, irritation in vagina, burning sensation, a lack of awareness in developing countries limit the growth of the yeast infection treatment industry.
COVID-19 Impact Analysis
In reaction to supply chain disruptions, governments have adopted several initiatives. The European Medicines Agency, for example, has published guidance to pharmaceutical companies regarding the regulatory framework for coping with the issues of this epidemic. These efforts were designed to lessen the outbreak's impact on production and supply.
According to new 2020 reports, around one-third of patients with severe COVID-19 infection require intensive care and maybe fight another deadly infection: Aspergillosis, a terrible fungal infection caused by the Aspergillus fungus. As a result, researchers discovered that people with COVID-19 may be more susceptible to lung infections caused by fungal respiration. As a result, experts are working to conduct additional research in this area. Scientists began diagnosing COVID-19 patients with Mucormycosis during India's second wave of COVID-19 infections. The DCGI withdrew applications for Amphotericin B, which is used to treat mucormycosis, from five fungal medicine companies in May 2021. As a result, while the epidemic scenario is projected to stimulate demand for OTC products in the near term, the drop in the number of pharmaceuticals and drugs for diagnosis and disruptions in the supply chain may cause a temporary setback.
Yeast Infection Treatment Market Segment Analysis
The candida albicans segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Candida albicans segment growth is expected to boost over the forecast period, owing to increasing number of patients infected with candidiasis in developing regions. According to the Centers for Disease Control and Prevention (CDC), around 46,000 cases of healthcare-associated invasive candidiasis occur in the United States each year. According to the CDC, the 30-day all-cause (crude) death rate among persons with candidemia is around 30%.
Furthermore, in June 2021, the FDA has approved ibrexafungerp tablets (Brexafemme) as a one-day oral medication for vaginal yeast infections, which affect three out of every four women at some point in their lives. As a result, various market players' number of regulatory authority approvals for products is boosting the market growth.
Yeast Infection Treatment Market
| Metrics | Details |
| Market CAGR | 5.2% |
| Segments Covered | By Pathogen Type, By Infection Type, By Drug Type, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Yeast Infection Treatment Market Geographical Analysis
North America region holds the largest market share of the global yeast infection treatment market
North America dominated the yeast infection treatment market, followed by the Europe market. The rise in yeast infection and the number of occurrences of vaginal infections is a major driver of the market in the region. Furthermore, an increase in the burden of the urological patient population, sophisticated healthcare infrastructure, and advantageous reimbursement situations in the region are just a few of the anticipated to drive the yeast infection treatment market in North America.
According to the Centers for Disease Control and Prevention, vaginal candidiasis is the second-most frequent infection in the United States, with an estimated 1.4 million outpatient visits each year. The yeast infection treatment market in Europe is expected to follow the market in North America, owing to the rising prevalence of yeast infection, increasing cases of vaginal infection in women patients, and the introduction of new treatment options for yeast infections.
The incidence of fungal species infections, such as Candida Auris infections, is at an all-time high, a big worry for European healthcare settings. This fuels the region's desire for yeast infection therapy.
Yeast Infection Treatment Market Competitive Landscape
The yeast infection treatment market is a highly competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Basilea Pharmaceutical, Astellas, Paogen Biopharmaceutical, Nov Digm Therapeutics, Bayer, Prestige Consumer, SYNEXIS, Manusaketteva, Pestige Consumer, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the yeast infection treatment market globally. For instance, In January 2020, The US Food and Drug Association has approved a supplemental New Drug Application (sNDA) for the expanded indication of MYCAMINE (micafungin for injection) to treat invasive candidiasis in pediatric patients younger than four months of age.
Prestige Consumer Healthcare
Overview:
Prestige Consumer Healthcare is an American firm that sells branded over-the-counter healthcare and domestic cleaning products to mass merchandisers, drugstores, convenience stores, supermarkets, and online retailers.
Product Portfolio:
Monistat: This drug is used to treat yeast infections in the vaginal area. Tioconazole ointment relieves vaginal burning, itching, and discharge caused by this disorder. This is an azole antifungal drug. It acts by inhibiting the growth of the yeast (fungus) responsible for the illness.
